Rare disease
Pfizerās tafamidis faces competition from Alnylam and BridgeBio in rare disease market
Anika Sharma
Alnylam and BridgeBio are poised to enter the highly lucrative transthyretin amyloidosis cardiomyopathy (ATTR-CM) market with the backing of an ...
BioMarin R&D chief reveals two new pipeline candidates and strategy to sustain innovation
Anika Sharma
BioMarin, the California-based biotech giant, is embarking on a mission to create its most robust pipeline in history, with a ...
Phreesia Acquires MediFind to Enhance Patient Experience and Outcomes
SG Tylor
Phreesia, a software as a service (SaaS) firm specializing in life sciences and healthcare, has announced its acquisition of MediFind, ...
The CDC vaccination committee has scheduled a date in August to consider using Sanofi, Arizona’s Beyfortus RSV antibody
SG Tylor
Following its highly anticipated FDA approval on Monday, the respiratory syncytial virus (RSV) antibody developed by Sanofi and AstraZeneca is ...
LifeArc’s project for rare diseases will spend Ā£100 million on patient care
SG Tylor
Source – LifeArc LifeArc, a self-funded non-profit medical research organization and charity, has announced the launch of the Rare Disease ...
